GLENMARK PHARMACEUTICALS
|
The Current P/E Ratio of GLENMARK PHARMACEUTICALS is -208.33.
Share Price | ₹1,446.2 | May 15,2025 |
Market Cap | ₹40,810.4 Cr | |
Earnings-TTM | ₹-195.9 Cr | TTM-Consolidated Results |
Price/Earnings | -208.33x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹40,810.4 Cr] as on May 15,2025
(/) Earnings [ ₹-195.9 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -208.33x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay -208.33 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLENMARK PHARMACEUTICALS
PE Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 15.68x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 13.25x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2023 at 44.14x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does GLENMARK PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
GLENMARK PHARMACEUTICALS | -195.89 | -208.33 | 40,810.4 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,486.00 | 36.34 | 417,400.0 |
DIVIS LABORATORIES LTD | 2,067.00 | 79.75 | 164,844.0 |
CIPLA LTD | 5,291.05 | 22.93 | 121,328.0 |
TORRENT PHARMACEUTICALS LTD | 1,862.00 | 59.36 | 110,521.0 |
DR REDDYS LABORATORIES LTD | 5,703.50 | 18.07 | 103,043.0 |
MANKIND PHARMA LTD | 2,050.73 | 51.51 | 105,632.0 |
ZYDUS LIFESCIENCES LTD | 4,591.80 | 19.82 | 91,008.8 |
LUPIN LTD | 3,306.26 | 28.61 | 94,583.5 |
AUROBINDO PHARMA LTD | 3,500.25 | 20.19 | 70,683.6 |
ABBOTT INDIA LTD | 1,334.46 | 48.36 | 64,536.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK PHARMACEUTICALS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | -208.33x |
Max industry PE | 79.75x |
Median industry PE | 28.61x |
Average industry PE | 16.06x |
You may also like the below Video Courses